Leerink Partnrs Forecasts Weaker Earnings for AstraZeneca

AstraZeneca PLC (NASDAQ:AZN) – Analysts at Leerink Partnrs lowered their Q4 2024 EPS estimates for shares of AstraZeneca in a research report issued to clients and investors on Monday, October 28th. Leerink Partnrs analyst A. Berens now forecasts that the company will post earnings of $1.05 per share for the quarter, down from their prior estimate of $1.06. The consensus estimate for AstraZeneca’s current full-year earnings is $4.07 per share. Leerink Partnrs also issued estimates for AstraZeneca’s FY2026 earnings at $5.99 EPS.

Other equities research analysts have also issued research reports about the company. TD Cowen lifted their price objective on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Deutsche Bank Aktiengesellschaft cut shares of AstraZeneca from a “hold” rating to a “sell” rating in a research note on Friday, September 13th. Finally, Erste Group Bank upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, AstraZeneca has a consensus rating of “Moderate Buy” and a consensus price target of $89.75.

AstraZeneca Stock Performance

NASDAQ:AZN opened at $75.22 on Tuesday. AstraZeneca has a 1 year low of $60.47 and a 1 year high of $87.68. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.89 and a quick ratio of 0.69. The business has a fifty day simple moving average of $80.03 and a two-hundred day simple moving average of $78.68. The company has a market capitalization of $233.23 billion, a P/E ratio of 36.34, a P/E/G ratio of 1.39 and a beta of 0.46.

Institutional Trading of AstraZeneca

Large investors have recently modified their holdings of the business. McClarren Financial Advisors Inc. lifted its position in AstraZeneca by 320.8% during the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock valued at $25,000 after purchasing an additional 247 shares during the last quarter. GHP Investment Advisors Inc. purchased a new position in AstraZeneca in the second quarter worth $26,000. Pathway Financial Advisers LLC bought a new position in AstraZeneca in the first quarter valued at $29,000. Hobbs Group Advisors LLC purchased a new stake in AstraZeneca during the second quarter valued at about $35,000. Finally, Versant Capital Management Inc lifted its stake in AstraZeneca by 1,614.8% during the second quarter. Versant Capital Management Inc now owns 463 shares of the company’s stock worth $36,000 after purchasing an additional 436 shares during the last quarter. Institutional investors own 20.35% of the company’s stock.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.